Aviance Capital Partners LLC Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Aviance Capital Partners LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,661 shares of the biopharmaceutical company’s stock after selling 449 shares during the period. Aviance Capital Partners LLC’s holdings in Gilead Sciences were worth $1,431,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of GILD. OFI Invest Asset Management purchased a new position in shares of Gilead Sciences during the third quarter valued at approximately $26,000. Tompkins Financial Corp lifted its stake in shares of Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares during the period. Fortitude Family Office LLC purchased a new position in shares of Gilead Sciences during the 4th quarter worth $29,000. Rakuten Securities Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $33,000. Finally, Financial Connections Group Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at $40,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Cantor Fitzgerald decreased their price target on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 7th. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a research report on Wednesday, April 24th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 26th. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Finally, Barclays lowered their price objective on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research note on Monday, April 29th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Hold” and an average target price of $83.69.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.29% of the company’s stock.

Gilead Sciences Stock Up 1.2 %

NASDAQ GILD traded up $0.76 on Monday, reaching $65.54. The company had a trading volume of 7,186,870 shares, compared to its average volume of 7,456,667. The firm has a market capitalization of $81.60 billion, a PE ratio of 182.06, a P/E/G ratio of 1.31 and a beta of 0.22. The firm has a 50-day moving average of $70.40 and a 200-day moving average of $75.68. Gilead Sciences, Inc. has a 1 year low of $64.33 and a 1 year high of $87.86. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.98 and a quick ratio of 0.72.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. During the same period in the prior year, the firm earned $1.37 earnings per share. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 3.74 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.70%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s payout ratio is 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.